Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4429 studies found for:    "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Not yet recruiting Disulfiram in Recurrent Glioblastoma
Conditions: Glioma;   Glioblastoma
Interventions: Drug: Disulfiram;   Dietary Supplement: Copper;   Drug: Alkylating Agents
2 Completed A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
Condition: HIV Infections
Interventions: Drug: Nelfinavir mesylate;   Drug: Lamivudine;   Drug: Filgrastim;   Drug: Stavudine;   Drug: Cyclophosphamide
3 Recruiting PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Conditions: Primary Myelofibrosis;   Myeloproliferative Disorders
Interventions: Procedure: Allogeneic hematopoietic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Drug: Ruxolitinib
4 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
5 Recruiting GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Conditions: Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia;   Mixed-Lineage Acute Leukemias
Interventions: Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Bendamustine
6 Completed A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Conditions: Ovarian Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female
Interventions: Drug: Trabectedin;   Drug: Dexamethasone
7 Recruiting Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Follicular Lymphoma, Grade 3b;   Transformed Lymphoma / DLBCL
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
8 Recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
9 Active, not recruiting Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immune System Diseases
Interventions: Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Procedure: Allogeneic hematopoietic stem cell transplantation
10 Terminated
Has Results
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: SGN-30
11 Completed A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Conditions: Breast Neoplasms;   Neoplasms;   Neoplasms by Site;   Breast Diseases;   Skin Diseases
Intervention: Drug: ET743
12 Not yet recruiting INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Condition: Glioblastoma
Interventions: Drug: Temozolomide;   Drug: Neratinib;   Drug: CC-115;   Drug: Abemaciclib
13 Not yet recruiting Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
Conditions: Astrocytoma;   Brainstem Glioma;   Ependymoma;   Mixed Glioma;   Oligodendroglioma;   Optic Nerve Glioma
Interventions: Radiation: Radiation therapy;   Drug: Temozolomide;   Procedure: Stem cell collection;   Procedure: Stem cell infusion
14 Not yet recruiting Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
Condition: High Grade Glioma
Interventions: Procedure: LITT;   Radiation: Radiation therapy;   Drug: Temozolomide
15 Recruiting TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Conditions: Brain Tumor;   Astrocytoma;   Astroglioma;   Glioblastoma;   Gliosarcoma
Interventions: Drug: TG02;   Drug: TMZ
16 Not yet recruiting Trabectedin Maintenance Post 1st-line in STS
Condition: Sarcoma, Soft Tissue
Intervention: Drug: Trabectedin
17 Recruiting Regorafenib in Relapsed Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: Regorafenib;   Drug: Lomustine
18 Not yet recruiting A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab
19 Recruiting Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Conditions: Glioblastoma;   Malignant Glioma
Interventions: Drug: MRZ;   Drug: TMZ;   Radiation: RT
20 Not yet recruiting Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Conditions: Glioblastoma;   Oligodendroglioma;   Anaplastic Oligodendroglioma
Interventions: Drug: RRx-001 dose escalation with TMZ + RT;   Radiation: Radiation;   Drug: Fixed dose Temozolomide (75 mg/m2);   Drug: Fixed RRx-001 weekly;   Drug: Staged TMZ and RRx-001 escalation in maintenance stage;   Drug: TMZ Maintenance

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.